Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 22 of 22
Leveraging clinical genomics for candidate neoantigen discovery
Eliezer M. Van Allen
Dana-Farber Cancer Inst., Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 8:00 AM-10:00 AM
Navigating the known and unknown challenges in the development of a selective NTRK inhibitor: The larotrectinib story
Keith T Flaherty
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 10:20 AM-12:20 PM
Job's dilemma for the genome: Why bad things happen to good chromosomes
David Pellman
Dana-Farber Cancer Institute, Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
Building personal cancer vaccines
Patrick Ott
Dana-Farber Cancer Inst., Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 8:00 AM-10:00 AM
Immunopeptidomics: Accelerating the development of personalized cancer immunotherapy
Michal Bassani-Sternberg
CHUV, Ludwig Cancer Research Center, Lausanne, Switzerland
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 8:00 AM-10:00 AM
Insertion-and-deletion-derived tumor-specific neoantigens and the immunogenic phenotype: A pan-cancer analysis
Samra Turajlic
The Royal Marsden NHS Foundation Trust, London, United Kingdom
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 8:00 AM-10:00 AM
NCI-MATCH: A new paradigm in the era of genomic oncology
Alice P. Chen
National Cancer Institute, Bethesda, MD, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 10:20 AM-12:20 PM
The National Lung Matrix Trial (NLMT): Challenges and opportunities
Gary Middleton
University of Birmingham, Birmingham, United Kingdom
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 10:20 AM-12:20 PM
Implementing genomic-driven basket clinical trials
José Baselga
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 10:20 AM-12:20 PM
Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments
Henry Qixiang Li
Crown Bioscience, Inc., Beijing, China
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 10:20 AM-12:20 PM
Chromosomal instability as a driver of tumor metastasis
Samuel F Bakhoum
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
Mechanisms of aneuploidy-driven tumorigenesis
Stephen J. Elledge
Harvard Medical School, Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures
Thomas G. Graeber
UCLA, Los Angeles, CA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
Structure of the blood-tumor barrier and potential ways to overcome it
Patricia S. Steeg
National Cancer Inst., Bethesda, MD, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
Immunotherapy for central nervous system cancers
John H. Sampson
Duke Univ. Medical Ctr., Durham, NC, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
Cancer drug distribution in the brain: PET imaging as a tool
E.G. Elisabeth de Vries
Univ. Medical Ctr. Groningen, Groningen, Netherlands
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
Systematic elucidation and pharmacologic targeting of mechanistic tumor dependencies
Andrea Califano
Columbia Univ., New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
Genetics and mechanisms of chemotherapy resistance in acute lymphoblastic leukemia
Adolfo Ferrando
Columbia Univ., New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
How Ras and Myc cooperate to drive cancers
Gerard I. Evan
University of Cambridge, Cambridge, United Kingdom
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
Targeting metabolic vulnerabilities in cancer
Dimitrios Anastasiou
Harvard Medical School, Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
Are we ready for metabolic editing yet?
Angela T Alistar
Carol G. Simon Cancer Center, Morristown, NJ, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
Targeting the metabolic basis of kidney cancer
W. Marston Linehan
National Cancer Inst., Bethesda, MD, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 22 of 22